康惠制药(603139) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥117,729,916.33, representing a year-on-year increase of 21.68%[4] - The net profit attributable to shareholders was ¥8,791,930.72, showing a decrease of 3.44% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥7,837,432.34, which is an increase of 8.51% year-on-year[4] - The net profit for the first quarter of 2022 was CNY 9,153,640.00, an increase of 9.25% compared to CNY 8,376,450.68 in the same period of 2021[25] - The total profit for the first quarter of 2022 was CNY 11,263,451.56, up from CNY 10,452,555.93 in Q1 2021, reflecting a growth of 7.75%[25] - Operating profit for the first quarter of 2022 reached CNY 11,419,086.29, compared to CNY 10,580,400.70 in Q1 2021, indicating an increase of 7.95%[25] - The total comprehensive income for the first quarter of 2022 was CNY 9,153,640.00, compared to CNY 8,376,450.68 in Q1 2021, reflecting an increase of 9.25%[27] Cash Flow - The net cash flow from operating activities reached ¥24,685,902.03, a significant increase of 235.92% compared to the previous year[4] - Cash flow from operating activities generated a net amount of CNY 24,685,902.03, a significant improvement from a net outflow of CNY 18,162,009.79 in the previous year[30] - Cash flow from investing activities resulted in a net outflow of CNY 66,682,283.18, compared to a net outflow of CNY 150,943,959.82 in Q1 2021, showing a reduction in cash outflow[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,838,053,085.62, down 1.19% from the end of the previous year[4] - Total assets as of March 31, 2022, amounted to ¥1,838,053,085.62, slightly down from ¥1,860,228,725.79 at the end of 2021[21] - Total liabilities decreased to ¥713,873,363.36 from ¥745,202,643.53 at the end of 2021, a reduction of 4.2%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,634[11] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., holds 39.65% of the shares and is subject to a pledge of 900,000 shares[11] Costs and Expenses - Total operating costs for Q1 2022 were ¥106,722,145.56, up from ¥87,868,202.45 in Q1 2021, reflecting a growth of 21.4%[23] - The company's financial expenses surged by 240.70%, primarily due to increased interest expenses on bank loans[7] - Research and development expenses increased to ¥1,445,540.79 in Q1 2022 from ¥1,309,336.56 in Q1 2021, showing a rise of 10.4%[23] Inventory and Receivables - Inventory as of March 31, 2022, was ¥117,081,713.09, a slight decrease from ¥119,892,500.02 at the end of 2021[16] - The company reported a significant increase in accounts receivable, which rose to ¥154,257,777.92 from ¥146,142,009.87, indicating a growth of 5.3%[16] Cash and Equivalents - Cash and cash equivalents as of March 31, 2022, were ¥162,546,662.27, down from ¥203,959,902.14 at the end of 2021, a decrease of 20.3%[16] - The company reported cash and cash equivalents at the end of Q1 2022 amounting to CNY 142,546,662.27, down from CNY 437,073,631.33 at the end of Q1 2021[32] Earnings Per Share - Earnings per share remained stable at CNY 0.09 for both basic and diluted earnings per share in Q1 2022[27] Credit Impairment - The company incurred a credit impairment loss of CNY -2,239,461.45 in Q1 2022, compared to CNY -407,830.56 in the same period of 2021, indicating a significant increase in credit losses[25]